JP7208650B2 - 癌治療のための薬剤の組み合わせ - Google Patents

癌治療のための薬剤の組み合わせ Download PDF

Info

Publication number
JP7208650B2
JP7208650B2 JP2020514327A JP2020514327A JP7208650B2 JP 7208650 B2 JP7208650 B2 JP 7208650B2 JP 2020514327 A JP2020514327 A JP 2020514327A JP 2020514327 A JP2020514327 A JP 2020514327A JP 7208650 B2 JP7208650 B2 JP 7208650B2
Authority
JP
Japan
Prior art keywords
cancer
compound
abtl0812
paclitaxel
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020514327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520385A5 (https=
JP2020520385A (ja
Inventor
ガルシア，カルレス ドメネク
アルホン コリアト，ホセ アルベルト
モントヨ，ヘクター ペレス
セグラ ギナード，ミゲール フランシスコ
リズカノ デ ベガ，ホセ ミゲール
Original Assignee
アビリティ ファーマシューティカルズ エス．エル．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アビリティ ファーマシューティカルズ エス．エル． filed Critical アビリティ ファーマシューティカルズ エス．エル．
Publication of JP2020520385A publication Critical patent/JP2020520385A/ja
Publication of JP2020520385A5 publication Critical patent/JP2020520385A5/ja
Application granted granted Critical
Publication of JP7208650B2 publication Critical patent/JP7208650B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020514327A 2017-05-16 2018-05-15 癌治療のための薬剤の組み合わせ Active JP7208650B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382282.6 2017-05-16
EP17382282 2017-05-16
PCT/EP2018/062554 WO2018210830A1 (en) 2017-05-16 2018-05-15 A pharmaceutical combination for the treatment of a cancer

Publications (3)

Publication Number Publication Date
JP2020520385A JP2020520385A (ja) 2020-07-09
JP2020520385A5 JP2020520385A5 (https=) 2021-07-26
JP7208650B2 true JP7208650B2 (ja) 2023-01-19

Family

ID=58765794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020514327A Active JP7208650B2 (ja) 2017-05-16 2018-05-15 癌治療のための薬剤の組み合わせ

Country Status (16)

Country Link
US (3) US11260042B2 (https=)
EP (2) EP4234035A3 (https=)
JP (1) JP7208650B2 (https=)
KR (1) KR102569052B1 (https=)
CN (2) CN110636842A (https=)
AU (1) AU2018269462B2 (https=)
BR (1) BR112019023944A2 (https=)
CA (1) CA3063625A1 (https=)
CL (1) CL2019003288A1 (https=)
ES (1) ES2955524T3 (https=)
HU (1) HUE063275T2 (https=)
IL (1) IL270676B2 (https=)
MX (1) MX2019013683A (https=)
PL (1) PL3624786T3 (https=)
WO (1) WO2018210830A1 (https=)
ZA (1) ZA201907286B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102569052B1 (ko) * 2017-05-16 2023-08-22 어빌리티 파마슈티컬스 에스.엘. 암의 치료를 위한 약제학적 조합물
WO2021160650A1 (en) * 2020-02-10 2021-08-19 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer
CN120733048A (zh) * 2025-08-29 2025-10-03 天津医科大学总医院 一种用于治疗肺鳞癌的药物组合物及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000517339A (ja) 1996-09-04 2000-12-26 スコシア ホールディングス ピーエルシー 脂肪酸による治療
JP2012520344A (ja) 2009-03-16 2012-09-06 リポファーマ セラピューティクス、エス．エル 多価不飽和脂肪酸ヒドロキシ誘導体及びその薬物としての使用
JP2014530806A (ja) 2011-10-07 2014-11-20 ウニベルシダッド・デ・レス・イレス・バレアルス 脂肪酸の２−ヒドロキシド誘導体のエナンチオマー

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258816A (ja) * 1987-04-16 1988-10-26 Nippon Oil & Fats Co Ltd 抗癌剤組成物
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
AU5928599A (en) * 1999-09-09 2001-04-10 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
GB0011903D0 (en) 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
RU2284818C2 (ru) 2001-05-10 2006-10-10 Анормед, Инк. Комбинированная химиотерапия
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
SG175401A1 (en) 2009-05-08 2011-12-29 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
ES2601891T3 (es) 2011-10-18 2017-02-16 Nestec S.A. Composición para su uso en crecimiento cerebral y/o desarrollo cognitivo y/o psicomotor
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
KR102569052B1 (ko) * 2017-05-16 2023-08-22 어빌리티 파마슈티컬스 에스.엘. 암의 치료를 위한 약제학적 조합물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000517339A (ja) 1996-09-04 2000-12-26 スコシア ホールディングス ピーエルシー 脂肪酸による治療
JP2012520344A (ja) 2009-03-16 2012-09-06 リポファーマ セラピューティクス、エス．エル 多価不飽和脂肪酸ヒドロキシ誘導体及びその薬物としての使用
JP2014530806A (ja) 2011-10-07 2014-11-20 ウニベルシダッド・デ・レス・イレス・バレアルス 脂肪酸の２−ヒドロキシド誘導体のエナンチオマー

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ability Pharma: Press Release (Dec. 14, 2016), "Ability Pharmaceuiticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer"
Ability Pharma: Press Release (Nov. 22, 2016), "Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Therapy in Patients with Endometrial or Squamous Lung Cancer Patients"
Clin Cancer Res，2016年，22(10)，pp.2508-2519
Journal of Clinical Oncology，2013年，31(15 suppl.)，e13526

Also Published As

Publication number Publication date
EP4234035A3 (en) 2023-11-15
HUE063275T2 (hu) 2024-01-28
US11260042B2 (en) 2022-03-01
RU2019135507A3 (https=) 2021-09-03
EP3624786C0 (en) 2023-07-05
KR102569052B1 (ko) 2023-08-22
KR20200005573A (ko) 2020-01-15
US12280033B2 (en) 2025-04-22
CN119950727A (zh) 2025-05-09
RU2019135507A (ru) 2021-06-16
PL3624786T3 (pl) 2023-10-30
EP3624786A1 (en) 2020-03-25
ES2955524T3 (es) 2023-12-04
CA3063625A1 (en) 2018-11-22
US20210154166A1 (en) 2021-05-27
BR112019023944A2 (pt) 2020-06-09
US12053449B2 (en) 2024-08-06
WO2018210830A1 (en) 2018-11-22
EP3624786B1 (en) 2023-07-05
IL270676B2 (en) 2024-11-01
US20220257554A1 (en) 2022-08-18
CL2019003288A1 (es) 2020-05-08
AU2018269462B2 (en) 2024-04-18
EP4234035A2 (en) 2023-08-30
AU2018269462A1 (en) 2019-11-28
ZA201907286B (en) 2021-01-27
CN110636842A (zh) 2019-12-31
IL270676B1 (en) 2024-07-01
US20240350449A1 (en) 2024-10-24
IL270676A (https=) 2020-01-30
JP2020520385A (ja) 2020-07-09
MX2019013683A (es) 2020-01-15

Similar Documents

Publication Publication Date Title
US12280033B2 (en) Pharmaceutical combination for the treatment of a cancer
EP3750530B1 (en) Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
EP3169312B1 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
TWI329025B (en) Compositions for delivery of drug combinations
KR101943230B1 (ko) 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
KR102712584B1 (ko) 종양 치료에 사용하기 위한 코르텍솔론의 17ａ,21-디에스테르
TWI447113B (zh) 醫藥組合
JPWO2012147901A1 (ja) 抗癌剤副作用改善用組成物
US11389536B2 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
RU2801665C2 (ru) Фармацевтическая комбинация для лечения рака
HK40098371A (en) A pharmaceutical combination for the treatment of a cancer
Neitzel Synergism of Lipoates and Established Anticancer Drugs in Cell and Mouse Models of Colorectal Cancer
HK40120326A (zh) 用於治疗癌症的药物组合
RU2821529C2 (ru) 17a,21-диэфиры кортексолона для применения в лечении опухолей
CN103599098A (zh) 姜黄素与银杏内酯b配伍组合物及其应用
HK40026959A (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
HK40008907A (en) Pharmaceutical composition for preventing and treating pancreatic cancer, containing gossypol and phenformin as active ingredients
HK1237267A1 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
HK1237267B (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
CZ201690A3 (cs) Inhibitory tyrozinových kináz v kombinaci s cytostatiky a nesteroidními antirevmatiky

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20191115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221226

R150 Certificate of patent or registration of utility model

Ref document number: 7208650

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250